Novel long-term anticonvulsant treatment with gabapentin without causing memory impairment in mice

Epilepsy and Behavior

Volumn 17, Issue 2, 2010, Pages 157-164

  Blake, Mariano G ^a,b   Boccia, Mariano M ^a,b   Carcaboso, Ángel M ^a   Chiappetta, Diego A ^b,c   Höcht, Christian ^a   Krawczyk, María C ^a   Sosnik, Alejandro ^b,c   Baratti, Carlos M ^a,b  

^a Lab Cellular Immunology   (Argentina)

^b National Science Research Council ^*  (Argentina)

^c Faculty of Pharmacy and Biochemistry   (Argentina)

Author keywords

Acetylcholine; Antiepileptic drugs; Drug delivery systems; Epilepsy; Gabapentin; Inhibitory avoidance; Kindling; Memory; Mice; Pentylenetetrazole

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; PENTETRAZOLE; POLYCAPROLACTONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CHOLINERGIC SYSTEM; CHRONIC DRUG ADMINISTRATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; LONG TERM CARE; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MOUSE; NONHUMAN; REPEATED DRUG DOSE; TONIC CLONIC SEIZURE;

AMINES; ANIMALS; ANTICONVULSANTS; COGNITION DISORDERS; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; KINDLING, NEUROLOGIC; MALE; MEMORY DISORDERS; MICE;

EID: 75749146951     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.12.005     Document Type: Article

References (38)

1. Dodrill C.B. Behavioral effects of antiepileptic drugs. Adv Neurol 55 (1991) 213-224
2. McGaugh J.L. Drug facilitation of learning and memory. Annu Rev Pharmacol Toxicol 13 (1973) 229-241
3. Blake M.G., Boccia M.M., Acosta G.B., Höcht C., and Baratti C.M. Opposite effects of a single versus repeated doses of gabapentin on retention performance of an inhibitory avoidance response in mice. Neurobiol Learn Mem 87 (2007) 192-200
4. Chang B.S., and Lowenstein D.H. Epilepsy. N Engl J Med 349 (2003) 1257-1266
5. Meador K.J. Cognitive outcomes and predictive factors in epilepsy. Neurology 58 (2002) S21-S26
6. Carreño M., Donaire A., and Sánchez-Carpintero R. Cognitive disorders associated with epilepsy: diagnosis and treatment. Neurologist 14 (2008) S26-S34
7. Vermeulen J., and Aldenkamp A.P. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 22 (1995) 65-95
8. Litter M. Farmacología experimental y clínica (1985), El Ateneo, Buenos Aires
9. Dichter M.A., and Brodie M.J. New antiepileptic drugs. N Engl J Med 13 (1996) 1583-1590
10. Taylor C.P., Gee N.S., Su T.Z., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29 (1998) 233-249
11. Steinman M.A., Harper G.M., Chren M.M., Landefeld C.S., and Bero L.A. Characteristics and impact of drug detailing for gabapentin. PLoS Med 4 (2007) 743-751
12. Shannon H.E., and Love P.L. Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats. Epilepsy Behav 5 (2004) 857-865
13. Shannon H.E., and Love P.L. Effects of antiepileptic drugs on attention as assessed by a five-choice serial reaction time task in rats. Epilepsy Behav 7 (2005) 620-628
14. Carpay J., Aldenkamp A., and van Donselaar C. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 14 (2005) 198-206
15. Meador K.J. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res 68 (2006) 63-67
16. Acosta G.B., Boccia M.M., and Baratti C.M. Gabapentin, an antiepileptic drug, improves memory storage in mice. Neurosci Lett 279 (2000) 173-176
17. Boccia M.M., Acosta G.B., and Baratti C.M. Memory improving actions of gabapentin in mice: possible involvement of central muscarinic cholinergic mechanism. Neurosci Lett 311 (2001) 153-156
18. Blake M.G., Boccia M.M., Acosta G.B., et al. Posttraining administration of pentylenetetrazol dissociates gabapentin effects on memory consolidation from that on memory retrieval process in mice. Neurosci Lett 368 (2004) 211-215
19. Carcaboso A.M., Chiappetta D., Höcht C., et al. In vitro/in vivo characterization of melt molding gabapentin-loaded poly(ε-caprolactone) implants for sustained release in animals studies. Eur J Pharmacol Biopharmacol 70 (2008) 666-673
20. Blake M.G., Boccia M.M., and Baratti C.M. Behavioral differences on memory retrieval between two variants of step-through inhibitory avoidance task in mice. Neurosci Lett 444 (2008) 102-105
21. Izquierdo I., and McGaugh J.L. Behavioural pharmacology and its contribution to the molecular basis of memory consolidation. Behav Pharmacol 11 (2000) 517-534
22. Archer T., Ross S.B., and Minor B.G. Attenuation of the postdecapitation convulsions after repeated treatment of rats with desipramine, imipramine and maprotiline. Acta Pharmacol Toxicol 54 (1984) 372-378
23. Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 32 (1972) 281-294
24. Rerup C., and Lundquist I. Blood glucose level in mice: evaluation of a new technique of multiple serial sampling. Acta Endocrinol (Copenhague) 52 (1966) 357-367
25. 3H]-dopa in various regions of the brain. J Neurochem 13 (1966) 655-669
26. Tang P.H., Miles M.V., Glauser T.A., et al. Automated microanalysis of gabapentin in human serum by high-performance liquid chromatography with fluorometric detection. J Chromatogr B 727 (1999) 125-129
27. Siegel S. Non-parametric statistics for the behavioral sciences (1956), McGraw-Hill, New York
28. Perrin D., and English J. Polycaprolactone. In: Domb A., Kost Y., and Wiseman D. (Eds). Handbook of biodegradable polymers: drug targeting and delivery (1997), Academic Press, New York 63-77
29. Kumar N., Ravikumar N.V., and Domb A.J. Biodegradable block copolymers. Adv Drug Deliv Rev 53 (2001) 23-44
30. Rathbone M.J., Bunta C.R., Oglea C.R., et al. Development of an injection molded poly(ε-caprolactone) intravaginal insert for the delivery of progesterone to cattle. J Control Release 85 (2002) 61-71
31. Sinha V.R., Bansal K., Kaushik R., et al. Poly-ε-caprolactone microspheres and nanospheres: an overview. Int J Pharmacol 278 (2004) 1-23
32. Boccia M.M., Blake M.G., Acosta G.B., et al. Memory consolidation and reconsolidation of an inhibitory avoidance response in mice: effects of i.c.v. injections of hemicholinium-3. Neuroscience 124 (2004) 735-741
33. Glien M., Brandt C., Potschka H., et al. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43 (2002) 350-357
34. Cundy K.C., Annamalai T., Bu L., et al. XP13512 [(±)-1-([(α-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311 (2004) 324-333
35. Cundy K.C., Sastry S., Luo W., et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 48 (2008) 1378-1388
36. Gordi T., Hou E., Kasichayanula S., et al. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 30 (2008) 909-916
37. Irving G., Jensen M., Cramer M., et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 25 (2009) 185-192
38. Jensen M.P., Chiang Y.K., and Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin J Pain 25 (2009) 286-292